To hear about similar clinical trials, please enter your email below
Trial Title:
Assessment of the Diagnostic Role of Serum Insulin-like Growth Factor Binding Protein-3 as a Potential Biomarker for Colorectal Cancer (CRC) in Egypt
NCT ID:
NCT05850559
Condition:
Colorectal Cancer
Conditions: Official terms:
Colorectal Neoplasms
Mitogens
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
evaluation of diagnostic importance of insulin like growth factor binding protein3 in patient with recently diagnosed as Colorectal cancer
Description:
evaluation of diagnostic importance of insulin like growth factor binding protein3 in
patient with recently diagnosed as Colorectal cancer by Enzyme-linked immunosorbent assay
(ELISA
Summary:
1. evaluation of diagnostic importance of insulin like growth factor binding protein3
in patient with recently diagnosed as Colorectal cancer
2. correlation between the diagnostic efficacy of insulin like growth factor binding
protein 3 with routine marker carcinoembryonic antigen.
Detailed description:
Colorectal Cancer is the third most common cancer diagnosed in the USA and the world's
fourth most deadly cancer .the incidence and the mortality rate of colorectal cancer has
decreased due to effective cancer screening measures.
Besides an ageing population and dietary habits of high-income countries, unfavourable
risk factors such as obesity, lack of physical exercise, and smoking increase the risk of
colorectal cancer.
The incidence of early-onset colorectal cancer diagnosed in patients under the age of 50
years- has been increasing around the world.
The insulin-like growth factor (IGF) system composed of two ligands, their receptors and
regulatory proteins.
IGFBPs regulate the cell cycle, and the function of IGFBPs in transcriptional regulation,
DNA damage repair and apoptosis induction suggest that they are closely associated with
tumour development, progression, and therapy resistance.
Insulin-like growth factor peptides play important roles in regulating cell growth, cell
differentiation, and apoptosis, and have been demonstrated to promote the development of
colorectal cancer.
Researchers found that IGFBP3 has the potential to be used as early indicator for
colorectal cancer diagnosis.
Moreover, IGFBP3 as a risk factor for carcinogenesis has been demonstrated in many
cancers.
IGFBP3 as a tumour suppressor was reported to be down-regulated in some cancers. But some
other publications showed its overexpression is associated with poor prognosis for
several cancers including pancreatic endocrine neoplasms.
Meanwhile, epidemiological studies indicated that higher circulating IGFBP3 level were an
increased risk of breast cancer.
Criteria for eligibility:
Study pop:
A calculated minimum sample of 50 patients diagnosed with Colorectal cancer and 30
apparently healthy subject with matched age and sex as acontrol group.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Patients at South Egypt Cancer institute and diagnosed Colorectal cancer patients
2. Patients not went to surgery
Exclusion Criteria:
1. patients receive any anti-cancer therapy.
2. Patients diagnosed with other concomitante cancer or chronic diseases
Gender:
All
Minimum age:
18 Years
Maximum age:
80 Years
Start date:
October 5, 2023
Completion date:
October 1, 2026
Lead sponsor:
Agency:
Assiut University
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05850559
